Quantcast
Last updated on April 16, 2014 at 13:30 EDT

Latest TNF inhibitor Stories

2011-11-07 01:00:00

ATLANTA, Nov. 7, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia® (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9. The data sets include new findings on patient-reported improvements in quality of life measures, including work and household productivity, in patients taking...

2011-11-06 05:00:00

ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively. In both studies, patients were assessed for disease activity,...

2011-11-05 23:30:00

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis have a higher risk of developing malignant melanoma. Chicago, Illinois (PRWEB) November 05, 2011 According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid...

2011-11-02 05:00:00

ABBOTT PARK, Ill., Nov. 2, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago. The presentations include data on rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and spondyloarthritis (SpA), as well as health...

2011-10-31 09:00:00

ATLANTA, Oct. 31, 2011 /PRNewswire/ -- UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia® (certolizumab pegol) at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2. "Cimzia data presented this year at ACG highlights the role that inflammatory biomarkers may play in increasing the understanding of the...

2011-09-28 08:20:01

Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch Humira(R) (adalimumab) Prefilled Syringe 20mg/0.4mL, a fully human anti-TNF-α monoclonal antibody for the treatment of polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight, on September 29.Humira Prefilled Syringe 20mg/0.4mL received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare on July 1 of this...

2011-09-26 04:20:01

Tokyo, Sept 26, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have submitted an application in Japan seeking approval of inhibition of structural damage of joints in rheumatoid arthritis as an additional indication for Humira(R) (adalimumab; recombinant) Pre-filled Syringe 40 mg/0.8 mL, a fully human anti-TNF-alpha monoclonal antibody jointly developed by the two companies.The submission is based on the results of a double-blind study (HOPEFUL1...

2011-09-23 15:54:00

HORSHAM, Pa., Sept. 23, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. This marks the 16th approval of REMICADE® in the U.S. and the seventh for the anti-tumor necrosis factor (TNF)-alpha in the...

2011-09-08 09:46:14

Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta analysis Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases. Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of...

2011-08-22 12:01:00

UPPSALA, Sweden and COPENHAGEN, Denmark, August 22, 2011 /PRNewswire/ -- Phadia AB and Biomonitor A/S announced today a collaboration in the field of immunogenicity testing and monitoring of patients treated with biopharmaceutical drugs. (Logo: http://www.newscom.com/cgi-bin/prnh/20101208/425503 ) "The addition of BioMonitor's iLite technology to our portfolio makes us the most complete supplier of solutions for Anti-Drug Antibody (ADA) testing," says Hans...